Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07433569 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma
A Phase 1 study of Asthma, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 6
- Study locations
NCT07433569: Recruiting Phase 1 study of Asthma, sponsored by AstraZeneca.
NCT07433569 is a Phase 1 study of Asthma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 12 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07433569, a Phase 1 study of Asthma, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to assess the pharmacokinetics (PK) and safety of symbicort aerosphere and symbicort pressurized metered dose inhaler (pMDI) in participants with asthma aged 4 to less than 12 years.
Primary Outcome
To determine and compare the systemic availability (Cmax) of budesonide and formoterol after single doses of Symbicort Aerosphere and Symbicort pMDI in participants 4 to less than 12 years of age with asthma.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Budesonide/formoterol fumarate Aerosphere
- COMBINATION_PRODUCT Budesonide/formoterol fumarate pMDI
Study Locations (6)
Texas
- Research Site - Boerne
- Research Site - El Paso
California
- Research Site - Long Beach
Florida
- Research Site - Miami
Louisiana
- Research Site - Lafayette
Ohio
- Research Site - Toledo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-03-05 |
| Est. Completion | 2026-10-22 |
| Phase | Phase 1 |
What NCT07433569 shows while recruiting
NCT07433569 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Budesonide/formoterol fumarate Aerosphere is the first listed.
NCT07433569 lists 6 locations in 5 states (Texas, California, Florida).
Frequently Asked Questions
What is clinical trial NCT07433569 about?
NCT07433569 is a clinical study titled "A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma". The purpose of this study is to assess the pharmacokinetics (PK) and safety of symbicort aerosphere and symbicort pressurized metered dose inhaler (pMDI) in participants with asthma aged 4 to less than 12 years.
What is the current status of trial NCT07433569?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2026-03-05. Estimated completion is 2026-10-22.
What conditions does trial NCT07433569 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT07433569?
The interventions under investigation include: Budesonide/formoterol fumarate Aerosphere (COMBINATION_PRODUCT), Budesonide/formoterol fumarate pMDI (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07433569?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07433569 being conducted?
This trial has 6 study locations across California, Florida, Louisiana, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07433569's enrollment target sits among peer trials
12 360th of 374 higher than 9 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
RECRUITING · Phase 1
-
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
RECRUITING · Phase 1
-
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
ACTIVE NOT RECRUITING · Phase 1
-
Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI